RxDoctor Payments Data

Vimal Ramjee, MD

Cardiovascular Disease · Chattanooga, TNNPI 1437383676

Payments from drug & device makers

$18,086in general payments, 2019–2025

Across 50 payments — averaging $361.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$10K
  • Viz.ai, Inc.$5K
  • Heartflow, Inc.$3K
  • Boston Scientific$517
  • Abbott$167
  • Terumo Medical Corporation$34
  • plus $118 from 7 others

What the payments were for

  • Consulting fees$15,67587%
  • Speaking & faculty fees$4002%
  • Travel & lodging$4813%
  • Food & beverage$1,5318%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,086 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$191,959
Medicare patients
2,043
Services billed
3,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban602$668,836
XareltoRivaroxaban126$143,206
Repatha SureclickEvolocumab80$88,232
EntrestoSacubitril/Valsartan80$88,180
JardianceEmpagliflozin15$20,974
Praluent PenAlirocumab17$9,746
Rosuvastatin Calcium479$7,576
Flecainide Acetate128$7,448
Bumetanide198$6,181
Atorvastatin Calcium469$5,829
Metoprolol Succinate303$5,221
Carvedilol575$5,073
Losartan Potassium241$3,066
Amiodarone Hcl132$3,005
Potassium Chloride102$2,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$668,836602 claims
Johnson & JohnsonXarelto$19$143,206126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →